Phase Zero and Phase One Trials

Definition: Phase One trials, also referred to as first-in-man trials, are the initial trials wherein new therapeutic strategies are tested on human subjects for the first time.
Purpose: The main goal of Phase One trials is to establish the optimum dose and administration schedule for subsequent Phase Two trials, ensuring a foundational understanding of the treatment's safety and pharmacological properties.

Objective: The primary endpoint of Phase One trials is to obtain the minimal amount of data necessary for progression to Phase Two trials.
Significance: This data is crucial for determining the safety and effective dosage for larger patient populations in later studies.

Although not mandatory for moving to Phase Two, several secondary endpoints provide valuable information.
Examples of Secondary Endpoints:
- Determining the optimal route of drug administration (oral vs. injected).
- Evaluating the half-life and stability of the drug within the human body.
- Assessing bioavailability: the extent and rate at which the active ingredient or active moiety is absorbed and becomes available at the site of action.
- Investigating efficacy: the ability of the drug to produce the desired biochemical effect in treating disease, bearing in mind the small scale will not provide statistical power.

Upside: Phase One trials can offer new hope to patients who have exhausted all existing treatment options, potentially leading to innovative therapies addressing unmet medical needs.
Downside: Patients may face higher risks of adverse effects since these therapies have not been previously tested in humans, resulting in a lower likelihood of therapeutic benefit.

Phase Zero and Phase One trials commence after significant preclinical development, including laboratory optimization, cell culture tests, biochemical assays, and animal model testing to show efficacy and safety before moving to human trials.
The aim is to gather information on dosing and pharmacological profiles through exploratory assessments.
Phase Zero trials proceed in the development pipeline but are even more investigative than Phase One, which aims to rigorously define the drug properties before mass testing.

Objective: Protecting intellectual property is essential to ensure that discoveries lead to profitable developments.
University Protocol: Institutions such as the University of Florida have offices dedicated to technology and licensing that evaluate disclosure of inventions and decide on prioritization considerations.
Patent Applications: Priority for discoveries is established through patent applications, which became significantly stricter post-2007; an invention disclosure alone no longer suffices.

Start with a Provisional Patent Application:
- Grants a 12-month period to further develop the invention.
- Allows the applicant to later convert to a full patent application, including new findings during the 12-month period.
Types of Protection:
- National (USA) or international (Japan, China, etc.) coverage.
- Broader protection generally incurs higher costs.

The IND (Investigational New Drug) Application must be filed with the FDA before proceeding to Phase One trials.
Requirements for a successful IND include:
- Comprehensive data on preclinical and animal pharmacology studies.
- Details on drug manufacturing, ensuring safety and purity.
- An approved clinical trial protocol to protect patient safety.

After filing the IND, an institution must receive approval from its IRB before initiating any clinical trials:
- The IRB ensures ethical conduct and minimizes risk to participants.
- Informed consent must be obtained from all participants after explaining the science involved in layman's terms.
Patient Protection Considerations:
- Compliance with HIPAA (Health Insurance Portability and Privacy Act) regarding patient health information.
- Proper handling of biological samples following safety training guidelines.

Standardized guidelines for clinical trial design, information recording, and result reporting are mandated to ensure the trials yield meaningful and useful outcomes.

Varies significantly based on drug type, ensuring safety, purity, and efficacy of produced drugs.
Compliance with these practices is crucial; failure may necessitate starting the trial process over.

Aim to find the safe therapeutic dose while monitoring for toxic levels:
- Rapid dose escalation can risk patient toxicity; slow escalation may not timely deliver potential therapeutic benefits.

Group patients: start with two to three patients receiving the lowest dose, monitoring for toxicities and collecting data on drug effects.
Gradually escalate doses until the maximum tolerated dose (MTD) is identified, where toxicity first occurs.

The MTD may not be the most rational endpoint due to receptor saturation at high doses.
Correct patient populations are necessary to observe efficacy; failures may lead to no therapeutic insights from traditional endpoints.
Most Phase One trials focus on monotherapy impacts, overlooking combination therapies that may yield different insights.

The FDA prioritizes first-in-class therapeutics or drugs that have no effective standard care to accelerate development processes.

Instead of solely using MTD, direct biochemical effects in target tissues at various concentration levels can be monitored to gauge efficacy.

In scenarios where targeting specific tissues is unavailable, measuring evidence of drug action in accessible tissues (e.g., white blood cells potentially reflecting tumor responses) can serve as a proxy for drug activity.

Pair a therapeutic agent with a responsive biomarker to assess drug activity directly, helping to discern whether the absence of efficacy is due to insufficient dosing or an inappropriate target.